Scarica l'app Stockscreener
2.35
2.08%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Anixa Biosciences Inc Borsa (ANIX) Ultime notizie
Anixa Biosciences Inc 3Q 2026: Net loss $(2.52M), EPS $(0.07) — 10-Q Summary - TradingView
[10-Q] Anixa Biosciences Inc Quarterly Earnings Report - Stock Titan
Number of shareholders of Anixa Biosciences, Inc. – GETTEX:CY71 - TradingView
Anixa Biosciences Holds Steady Near Support as Trading Volume Remains SubduedSuperTrend - The Legal Advocate
Anixa Biosciences (ANIX) Secures Patent for Ovarian Cancer Vacci - GuruFocus
Anixa Biosciences (ANIX) Secures Patent for Ovarian Cancer Vaccine Technology - GuruFocus
Anixa receives Canadian patent allowance for ovarian cancer vaccine By Investing.com - Investing.com Canada
Anixa receives Canadian patent allowance for ovarian cancer vaccine - Investing.com
Ovarian cancer vaccine targeting 'retired' protein wins Canada patent backing - Stock Titan
Anixa Biosciences (ANIX) Edges Higher, Tests Key Support ZoneArms Index - newsline.com
Anixa Biosciences (ANIX) Holds Steady at $2.73 as Consolidation ContinuesMomentum ETF - The Legal Advocate
Anixa Biosciences (ANIX) Slides 2.15% as Biotech Sector Headwinds ReturnPrice Action Signals - The Legal Advocate
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANIX Stock Price, Quote & Chart | ANIXA BIOSCIENCES INC (NASDAQ:ANIX) - ChartMill
Anixa Biosciences Issues Correction to May 11, 2026 Announcement, Details Available on StockTitan.net - geneonline.com
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-Cel Ovarian Cancer Car-T Therapy - marketscreener.com
Anixa Biosciences (ANIX) Reports Promising Survival Data from Cl - GuruFocus
Anixa reports survival data from ovarian cancer therapy trial - Investing.com UK
/C O R R E C T I O N -- Anixa Biosciences, Inc./ - PR Newswire
Anixa reports survival data from ovarian cancer therapy trial By Investing.com - Investing.com Australia
Anixa Biosciences Reports Updated Positive Survival Observations From Ongoing Phase 1 Trial Of Lira-Cel Ovarian Cancer CAR-T Therapy - TradingView
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy - StreetInsider
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer - Quantisnow
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - The Malaysian Reserve
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV - Investing News Network
Bloomberg TV to air Anixa CEO on cancer vaccine and CAR-T data - Stock Titan
Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ChartMill
Anixa Biosciences announces issuance of Mexican patent covering breast cancer vaccine technology - marketscreener.com
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology - The AI Journal
Anixa Biosciences (ANIX) Secures Patent for Breast Cancer Vaccine Technology - GuruFocus
Anixa Biosciences receives Mexican patent for breast cancer vaccine By Investing.com - Investing.com Australia
Anixa Biosciences receives Mexican patent for breast cancer vaccine - Investing.com
A breast cancer vaccine gained patent protection in Mexico until 2040 - Stock Titan
Anixa’s ovarian cancer therapy to be presented at ISCT meeting By Investing.com - Investing.com India
Anixa’s ovarian cancer therapy to be presented at ISCT meeting - Investing.com
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting - Nasdaq
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress - WFXG
Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference - Yahoo Finance
Weekly Trades: Does Anixa Biosciences Inc have declining or rising EPS2026 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Macro: Can Anixa Biosciences Inc maintain its current growth rate2026 Analyst Calls & Consistent Profit Trade Alerts - baoquankhu1.vn
AVAX Technologies and Anixa Biosciences Compared in Critical Analysis - National Today
Earnings Risk: Does Anixa Biosciences Inc have declining or rising EPSWeekly Trend Recap & Daily Growth Stock Investment Tips - baoquankhu1.vn
Anixa Biosciences to Participate in RedChip's Biotech Resurgence - GuruFocus
Anixa Biosciences Reports Positive Clinical Trial Results for Cancer Vaccines - Intellectia AI
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 - Finviz
At April 16 event, Anixa will spotlight 74% immune response data - Stock Titan
2.20%
2.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):